Search
Search
Pregnant women who use marijuana almost three times more likely to have low birth weight infant
In a new study, researchers in London, Ontario found that women who used marijuana while pregnant were almost three times more likely to have an infant with low birth weight than women who did not use marijuana.
The study analyzed data from perinatal and neonatal databases at London Health Sciences Centre (LHSC) and is the first large-scale study in Canada to show this association between marijuana use among pregnant women and low birth-weight infants.
It was conducted by researchers at Lawson Health Research Institute, Western University and Brescia University College.
Maternal amphetamine use, chronic hypertension and smoking were identified as other top risk factors for low birth weight. The study also examined predictors of preterm birth, which included previously diagnosed diabetes, maternal narcotic use and insulin-controlled gestational diabetes.
“Low birth weight and preterm birth are serious public health problems. Both are associated with a higher risk of infant mortality,” says principal investigator Dr. Jamie Seabrook, a Lawson associate scientist; and professor at Brescia University College, an affiliate of Western University, and Western University’s Schulich School of Medicine & Dentistry.
Low birth weight can lead to respiratory problems and asthma, and poor cognitive development during childhood. It also increases an infant’s risk of developing type 2 diabetes, hypertension and cardiovascular disease later in life. Preterm birth can cause childhood neurologic disability, as well as long-term medical consequences including respiratory, gastrointestinal and cardiovascular diseases and decreased immunity.
The research team investigated many potential factors that could be linked to birth outcomes, including demographics, prenatal factors and medical risks. The objective of the study was to determine the relationship between socioeconomic status and adverse birth outcomes, particularly low birth weight and preterm birth, in Southwestern Ontario.
However, they found that socioeconomic status had little influence on birth outcomes.
“There is a widely-held view that socioeconomic status is highly associated with low birth weight and preterm birth. However, there have been few population-based studies investigating this relationship in Canada. Most of this research has come from other developed countries, particularly the United States,” says Dr. Seabrook, who is also a Faculty Associate at Western’s Human Environments Analysis Laboratory. “It’s possible that Canada’s universal health care system provides a larger safety net for these mothers and their children.”
Live births between February 2009 and February 2014 at LHSC were included in the study. Infants with a birth weight of less than 2500 grams were classified as low birth weight. Preterm birth was defined as a live birth at a gestational age of less than 37 weeks.
The rates of low birth weight and preterm birth found in the study were 6.4 per cent and 9.7 per cent, respectively. The study notes that these rates are comparable to those reported by the Canadian Institute for Health Information in 2010-11, which found that 6.6 per cent of infants in Canada had low birth weight and 8.1 per cent were preterm births.
Median neighbourhood income was used as an indicator of socioeconomic status. Postal codes of the mothers were entered into a Geographic Information System and mapped to determine the location of home neighbourhoods, defined by boundaries of census dissemination areas. Dr. Seabrook adds that while the database used in the study included a large population-based sample, it is possible there may be incomplete or inaccurate data since it was obtained from chart records. For example, information on individual household income and length of time at an address was not available.
Along with Dr. Seabrook, the research team included Dr. Jason Gilliland, a scientist at Children’s Health Research Institute (a program of Lawson), Director of the Human Environments Analysis Laboratory at Western and professor at Schulich Medicine & Dentistry; Dr. Barbra de Vrijer, associate scientist at Children’s Health Research Institute, consultant in LHSC’s Obstetrics & Gynaecology department and associate professor at Schulich Medicine & Dentistry; Dr. Debbie Penava, Lawson scientist, LHSC physician and associate professor at Schulich Medicine & Dentistry; Dr. Paula Dworatzek, Chair and Associate Professor, School of Food and Nutritional Sciences at Brescia University College; and Emily Campbell, MScFN, RD, who was a graduate student at Brescia University College at the time of the study.
“Socioeconomic status and adverse birth outcomes: A population-based Canadian sample” was published in the Journal of Biosocial Science.
Above: Dr. Jamie Seabrook
Children's Health Leadership Collaborative (CHLC)
A partnership involving Children’s Hospital at London Health Sciences Centre (LHSC), Children’s Health Research Institute (CHRI), a part of Lawson Health Research Institute, and Thames Valley Children’s Centre (TVCC) if focused on a shared vision of advancing children’s health through a tripartite mission of research, education and clinical care.
The foundation of the Children’s Health Leadership Collaborative is a commitment of the aforementioned leadership to work collaboratively to optimize our collective and individual potential in health research in support of children’s health through integrated processes, initiatives, and objectives of mutual interest.
Prostate cancer imaging research could bring big benefits
LONDON, ON – With newly announced studies, Lawson Health Research Institute continues to lead the way in advancing prostate cancer imaging.
Scientists at Lawson are at the forefront of research that uses imaging agents that bind to a protein on the surface of prostate cancer cells called prostate specific membrane antigen (PSMA). Advanced imaging technology called PET/CT (positron emission tomography/computed tomography) and PET/MRI (magnetic resonance imaging) is then used to capture clear images of the location and extent of the cancer.
The first scan of its kind in Canada was captured at St. Joseph’s Health Care London in 2016 by Dr. Glenn Bauman, a Radiation Oncologist at the London Regional Cancer Program at London Health Sciences Centre and Scientist with Lawson.
“We started out with mainly MRI imaging but we've developed this very rigorous pipeline that allows us to put the imaging and digitized pathology together,” explains Dr. Bauman.
Early evidence indicates that PSMA PET scans have changed how prostate cancer is being treated, but more work is underway to understand the impact of those treatment changes. Working with imaging specialists there is hope that registries of these scans that are in development could even lead to automated detection of prostate cancer.
The Canadian Cancer Society recently committed $125,000 in funding for the creation of a database of PET/CT prostate cancer scans. Led by Dr. Katherine Zukotynski, an Adjunct Scientist at Lawson, the idea is to make annotated findings accessible to a wider community of medical and research professionals.
“If you have an idea of the amount of disease detected, correlated with what kind of prognosis, then this could be very helpful. It would allow oncologists to compare patients with similar cases, which may help determine the best therapies to try,” Dr. Zukotynski says.
Lawson has also become the first in Canada to enter a sublicense agreement to produce a new PET imaging agent called PSMA-1007 - that may produce even clearer images, especially when there’s a recurrence of cancer.
“PSMA-1007 allows us to detect where the cancer is a lot sooner and take action, whether that’s through surgery or delivering radiation to exactly where the cancer is located,” says Dr. Michael Kovacs, Director of the Lawson Cyclotron & PET Radiochemistry Facility.
Clinical trials have already begun to test PSMA-1007’s efficacy with an ultimate goal of obtaining Health Canada approval.
A three-part series on prostate cancer imaging at Lawson is also available:
Lawson Health Research Institute is one of Canada’s top hospital-based research institutes, tackling the most pressing challenges in health care. As the research institute of London Health Sciences Centre and St. Joseph’s Health Care London, our innovation happens where care is delivered. Lawson research teams are at the leading-edge of science with the goal of improving health and the delivery of care for patients. Working in partnership with Western University, our researchers are encouraged to pursue their curiosity, collaborate often and share their discoveries widely. Research conducted through Lawson makes a difference in the lives of patients, families and communities around the world. To learn more, visit www.lawsonresearch.ca.
Communications Consultant & External Relations
Lawson Health Research Institute
T: 519-685-8500 ext. ext. 64059
C: 226-919-4748
@email